Rosas PM, Lara EA, Pastelín HG, Velázquez MO, Martínez RJ, Méndez OA, Lorenzo NJ, Lomelí EC, González HA, Herrera AJ, Tapia CR, Attie F

Language: Spanish
References: 25
Page: 96-111
PDF size: 1023.86 Kb.

ABSTRACT

Objective: Based on a National Re-survey on Hypertension (HTA) and other cardiovascular risk factors performed in Mexico during 2003 and 2004 in the adult population with HTA, as identified in the 2000 National Survey of Health, this study was planed to determine: 1) morbidity and mortality rates; 2) the incidence and interrelation with other risk factors, such as overweight, obesity, dyslipidemia, nephropathy and diabetes; 3) the main risk factors associated to HTA involved in its complications, need for hospitalization and number of days; and, 4) the degree of therapeutical adhesion and the type of antihypertensive drugs used. Methods: The survey was of type III using the step by step method described by WHO. Sampling was weighed a priori taking into account a national prevalence average of HTA of 30.05% and its corresponding rate for each federal state. Permissible maximum error in the estimation = 0.28. Effect of design = 4.5; and, Rate of awaited answer (0.70). Results: From the initial 14,567 interviewed patients, 1,165 (8%) subjects were considered non-hypertensive or false positives at the 2000 survey. From the 13,402 remaining patients, 335 died during the first 2 years of pursuit, which implies an annual mortality of ~ 1.15% in the hypertensive population. Thus, 13,067 survivors were subjected to the final analysis. The mean age at the re-survey was 45.6 ± 12.6; 40.5% were men (n = 5,295). There was a statistically significant difference in height, but not in weight between both genders. The control HTA was raised 14.6% in the year 2000 and 19.2% in 2004. The prevalence of diabetes was duplicated from 16% to 30% (‹ .001). Fifty four percent of the whole population required hospitalization at least once during the period of study. The rates of overweight, obesity, and dyslipidemia rose significantly (p ‹ 0.05) independently from age, federal state, and gender. Conclusion: RENAHTA shows the impact of hypertension on the morbidity and mortality during the 3.1 ± 1.5 years of follow-up in Mexico. It alerts us on the need to reinforce the strategies of attention and prevention of this crucial risk factor and of screening the dynamic nonlinear interaction between the main cardiovascular risk factors in Mexico. New hypotheses are proposed for the metabolic syndrome.

REFERENCES

1. Guidelines Sub-Committee: 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/ International Society of Hypertension meeting. J Hypertens 1993; 11: 905-918.

2. Velásquez MO, Rosas PM, Lara EA, Pastelin GH, ENSA 2000, Attie F, Conyer T: Hipertensión Arterial en México. Arch Cardiol Mex 2002; 72: 71-84.

3. Guidelines Sub-Committee: 1999 World Health Organization–International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.

4. De Backer G, Graham I, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.

5. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.

6. Collins R, Peto R, MacMahon S, Herbert P, Fieback NH, Eberlein KA, et al: Blood pressure, stroke, and coronary heart disease. Part 2, Shortterm reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-839.

7. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.

8. Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.

9. Velásquez MO, Rosas PM, Lara EA, Pastelín G, ENSA 2000, Attie F, Conyer T: Prevalencia e interrelación de las Enfermedades Crónicas No Trasmisibles y Factores de riesgo Cardiovascular en México. Arch Cardiol Mex 2003; 73: 62-77.

10. Feinstein AR: Multivariable Analysis: An introduction. New Haven Connecticut: Yale University Press, 1996: 297-369.

11. Morbidity and Mortality Chartbook on Cardiovascular, Lung and Blood Disease -1990. Bethesda, Md: Government Printing Office; 1990. National Heart, Lung, and Blood Institute.

12. User´s Guide: SPSS for windows. Advanced Statistics release 10.0 Chicago: SPSS; 1999: 285-310.

13. Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001; 10: 190-192.

14. Primatesta P, Brookes M, Poulter NR: Improved hypertension management and control. Results from the Health Survey for England 1998. Hypertension 2001; 38: 827-832.

15. O’Rourke MF: From theory into practice. Arterial hemodynamics in clinical hypertension. J Hypertens 2002; 20: 1901-1915.

16. Lenfant C: Reflections of hypertension control rates. Arch Intern Med 2002; 162: 131-132.

17. Millar JA, Lever AF, Burke A: Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999; 17: 1065-1072.

18. Franklin S, Khan SA, Wong DA, Larson MG, Levy D: Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354-360.

19. Franklin S, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249.

20. Cranford L. Scott: Diagnosis, Prevention, and Intervention for the Metabolic Syndrome. Am J Cardiol 2003; 92(suppl): 35i-42i.

21. Meng S, Cason GE, Gannon AW, Racusen LC, Manning RD Jr: Oxidative Stress in Dahl Salt-Sensitive Hypertension. Hypertension 2003; 41: 1346-1352.

22. Johnson RJ, Herrera-Acosta, J, Schreiner GF, Rodriguez-Iturbe B: Mechanisms of Disease: Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension. N Engl J Med 2002; 346: 913-23.

23. AMERICAN HEART ASSOCIATION: 2002 Heart and Stroke Statistical Update. Dallas, Tex.: American Heart Association; 2001. americanheart.org

24. Murray cjl, Lopez AD: Evidence-based health policy lessons from the global burden of disease study. Science 1996; 274: 740-743.

25. Allison DB, Fontaine KR, Manson JE, Stevens J, Vanitallie T: Annual deaths attributable to obesity in the United States. JAMA 1999; 282(16): 1530-1538.